ArticleNanophotonics (Berlin, Germany)2022
NIR-II light-activated two-photon squaric acid dye with Type I photodynamics for antitumor therapy.
Article in Nanophotonics (Berlin, Germany), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Substrate-free generation of photosensitizer radical-ion pairs enables multipath photoredox for hypoxia-tolerant photodynamic therapy.Light, science & applications · 2026Article
- Charge Transfer Reactions (PDT Reaction I) Induced at 1064 nm (NIR-II) between Rhodamines and Folic Acid as the Basis for Biphotonic Photodynamic Therapy.Journal of fluorescence · 2025Article
- Targeting tumor angiogenesis and metabolism with photodynamic nanomedicine.Frontiers in cell and developmental biology · 2025Review
- Comparison of the Differences between Two-Photon Excitation, Upconversion, and Conventional Photodynamic Therapy on Cancers in In Vitro and In Vivo Studies.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Novel two-dimensional materials based bio-nanophotonics.Nanophotonics (Berlin, Germany) · 2022Article
- Erratum to: NIR-II light-activated two-photon squaric acid dye with type I photodynamics for antitumor therapy.Nanophotonics (Berlin, Germany) · 2022Article
Corrections and comments
- Erratum issued
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Photodynamic therapy (PDT) for hypoxic tumors has attracted wide attention owing to its noninvasiveness, easy maneuverability, and instantaneity. However, hypoxia in tumors and penetration depth of conventional ultraviolet light has greatly weakened its performance. To solve these problems, under NIR-II light irradiation, squaric acid nanoparticles (SQ NPs) with superior reactive oxygen, especially, hydroxyl radicals (•OH) production performance were first utilized for hypoxic tumor therapy. SQ NPs with intense light capture capability, intense NIR emission, and excellent photobleaching resistance show continuous •OH generation capabilities under NIR-II laser excitation. Through the superior PDT performance, the growth of hypoxic tumors was effectively inhibited, and the survival rate of mice was improved. This work highlights the application of NIR-II photoexcitation in deep tissue type I photodynamic therapy of hypoxic tumors, which will facilitate the development of hypoxic tumor PDT in deep depth.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.